SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Efmitermant alfa

Cat. No.: HY-P99920

CAS No.: 1644543-31-6

Target: Others

Pathway: Others

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Efmitermant alfa (ACE-083) is a locally acting, follistatin-based fusion protein. Efmitermant alfa also is a muscle-promoting agent. Efmitermant alfa can be used for the research of muscle disorders[1][2].

In Vitro

ACE-083 (0-60 nM) has high affinity for heparin and extracellular matrix[1].
ACE-083 (0- 20 μg/mL) binds and potently neutralizes myostatin, activin A, activin B and growth differentiation factor 11 (GDF11) [1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

ACE-083 (i.m.; 0-100 μg; twice weekly for 4 weeks) causes localized, dose-dependent hypertrophy of the injected muscle in wild-type mice and mouse models of Charcot-Marie-Tooth disease (CMT) and Duchenne muscular dystrophy[1].
ACE-083 (i.m.; 0-100 μg; twice weekly for 4 weeks) also increases the force of isometric contraction in situ by the injected tibialis anterior muscle in wild-type mice and disease models and increased ankle dorsiflexion torque in CMT mice[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wild-type mice; CMT mice; mdx mice[1]
Dosage:	1, 3, 10, 30 and 100 μg
Administration:	intramuscular; twice weekly for 4 weeks
Result:	Increased the weight of the injected muscle in a dose-dependent manner and caused focal growth of skeletal muscle in wild-type mice without evidence of systemic effects. Caused focal muscle hypertrophy accompanied by increased generation of absolute force, increased ankle dorsifexion torque and a benefcial change in a major biomarker of muscle atrophy. Caused focal growth of the injected muscle and increased generation of absolute force.

REFERENCES

[1]. R S Pearsall, et al. Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease. Sci Rep. 2019 Aug 6;9(1):11392.

[2]. Jeffrey M Statland, et al. Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy. Muscle Nerve

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA